Immunoglobulins Global Market Report 2024

Immunoglobulins, also known as antibodies, are glycoproteins produced by plasma cells, a type of white blood cell. These molecules play a crucial role in the immune response by selectively identifying and binding to specific antigens, such as viruses or bacteria, contributing to their elimination from the body.

The primary types of immunoglobulins include IgG, IgA, IgM, IgE, and IgD. Immunoglobulin G (IgG) is particularly significant as it is the main stimulator of humoral immunity in extracellular fluids like blood, lymph, and saliva. Each type of immunoglobulin serves a distinct function in the immune system's defense against various pathogens. These immunoglobulins are administered through different modes of delivery, including intravenous and subcutaneous routes. They find applications in treating conditions such as hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis, idiopathic thrombocytopenic purpura (ITP), and others. The therapeutic use of immunoglobulins helps address deficiencies in the immune system and manage autoimmune disorders, enhancing the body's ability to fight infections and maintain overall health.

The immunoglobulins market research report is one of a series of new reports that provides immunoglobulins market statistics, including immunoglobulins industry global market size, regional shares, competitors with a immunoglobulins market share, detailed immunoglobulins market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulins industry. This immunoglobulins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The immunoglobulins market size has grown strongly in recent years. It will grow from $17.49 billion in 2023 to $19.07 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth observed in the historic period can be attributed to several factors. These include an increased prevalence of immunodeficiency disorders, a growing geriatric population, rising adoption of immunoglobulins in hospitals, favorable government reimbursement plans, and an increasing prevalence of chronic and autoimmune diseases. These factors collectively contributed to the expansion of the immunoglobulins market during that time.

The immunoglobulins market size is expected to see rapid growth in the next few years. It will grow to $28.3 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The anticipated growth in the forecast period can be attributed to several factors. These include increasing investments in the development of advanced technologies, a growing awareness about immunodeficiency therapies, a rising preference among physicians for immunodeficiency therapies, an increasing number of emerging markets, and the expansion of applications in sports and fitness. These factors are expected to contribute to the continued expansion of the immunodeficiency therapy market in the forecasted period. Additionally, major trends in the forecast period include the development of wearable and smart compression devices, the customization of compression therapy solutions, the integration of compression therapy in wound care management, and an emphasis on patient comfort and compliance in compression therapy. Furthermore, collaborations between manufacturers and healthcare providers for improved patient outcomes are expected to shape the landscape of immunodeficiency therapies in the coming years. These trends indicate a dynamic and evolving market focused on technological advancements, personalized solutions, and enhanced patient care.

The growth of the immunoglobulins market is being propelled by the increasing geriatric population. This demographic is particularly susceptible to infectious and autoimmune diseases. Immunoglobulin tests are instrumental in assessing the body's ability to generate antibodies for safeguarding against bacteria, viruses, and allergies. For example, a report from the World Health Organization (WHO) in October 2022 revealed that by 2030, one in six individuals globally is projected to be 60 years or older. Additionally, it is estimated that by 2050, the worldwide population of individuals aged 60 or older will reach 2.1 billion. Consequently, the rising geriatric population is anticipated to drive demand for the immunoglobulins market throughout the forecast period.

The anticipated growth of the immunoglobulins market is further supported by an increase in healthcare expenditure. Healthcare expenditure encompasses the total financial outlay by individuals, organizations, and governments on healthcare-related services, treatments, medications, medical equipment, facilities, and healthcare administration. Elevated investment in the healthcare sector fosters research and development activities in immunoglobulins, potentially leading to the discovery of advanced therapies and augmenting market growth. A report published by the Centers for Medicare & Medicaid Services in March 2022 estimated an average annual increase of 5.1% in national health spending between 2021 and 2030, reaching nearly $6.8 trillion. Moreover, Medicare and Medicaid spending is projected to rise at annual rates of 7.2% and 5.6%, respectively, during the same period. Consequently, the escalating healthcare expenditure is a driving force behind the growth of the immunoglobulins market.

The evolution of the immunoglobulins market is influenced by the establishment of new offices and laboratories dedicated to research and development activities. Key players in the immunoglobulins sector are strategically opening new laboratories to enhance platform technology, pipeline development, and manufacturing capabilities. For instance, in February 2021, VectorY, a fully integrated gene therapy firm, inaugurated offices and laboratories in the Netherlands. These facilities are focused on developing novel vectorized antibodies for treating muscular and neurological illnesses. VectorY employs a revolutionary AAV platform and antibody-based targeted degradation technology in collaborative projects aimed at overcoming the limitations of current therapies and improving delivery, durability, and accessibility to specific tissues and cells.

Major companies in the immunoglobulins market are actively developing innovative products, including intravenous immunoglobulins, to expand their customer bases, boost sales, and increase revenue. Intravenous immunoglobulin (IVIG) is a therapeutic product composed of a concentrated solution of immunoglobulins found naturally in blood plasma. For example, in February 2021, Pfizer Inc., a US-based pharmaceutical company, secured FDA approval for PANZYGA. This unique product is the sole intravenous immunoglobulin (IVIg) offering two FDA-approved maintenance dosing alternatives for chronic inflammatory demyelinating polyneuropathy (CIDP), effectively meeting the clinical needs of patients. PANZYGA also allows for infusion rates of up to 12 mg/kg/min and is designed for adult individuals suffering from CIDP.

In October 2022, AbbVie Inc., a US-based pharmaceutical company, completed the acquisition of DJS Antibodies Ltd. for an undisclosed amount. This strategic move is expected to enhance AbbVie's existing antibody research efforts, strengthen its immunology portfolio, and establish a significant presence in the bioscience hub of Oxford, UK. The acquisition provides AbbVie with access to the HEPTAD platform, complementing its robust capabilities in biotherapeutics research. Simultaneously, DJS plans to leverage AbbVie's extensive expertise in drug discovery to advance antibody therapeutics and explore novel biological insights, particularly in challenging targets like GPCRs that have proven resistant to biologics-based approaches. DJS Antibodies Ltd. is a UK-based company specializing in antibody therapeutics.

Major companies operating in the in the immunoglobulins market report are Baxter International Inc., CSL Behring LLC, Grifols S. A., Octapharma AG, China Biologic Products Holdings Inc., Kedrion SpA, LFB SA, Biotest AG, Sanquin Blood Supply Foundation, ADMA Biologics Inc., Option Care Health Inc., Shanghai RAAS Blood Products Co. Ltd., Antibody Solutions, Blood Diagnostic Pharma Inc., Bio Products Laboratory Ltd., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Catalyst Biosciences Inc., Cytiva Corporation, Immunovant Inc., Kamada Ltd., Emergent BioSolutions Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., Roche Holding AG, Samsung Bioepis Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited

North America was the largest region in the immunoglobulins market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the immunoglobulins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The immunoglobins market consists of sales of antibodies, glycoproteins, and antigens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.